Abstract
The thiocarbonohydrazone 348U87 inactivates herpes simplex virus ribonucleotide reductase and potentiates the activity of acyclovir against wild-type and acyclovir-resistant strains of herpes simplex virus. We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study. Transient improvement with combination therapy occurred frequently; however, target lesions reepithelialized completely in only 1 of 10 patients. Termination of study drug therapy was most often due to cessation of therapeutic effect before complete resolution of lesions. As currently formulated, topical 348U87 offers little therapeutic benefit for this indication.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acyclovir / administration & dosage
-
Acyclovir / pharmacology
-
Acyclovir / therapeutic use*
-
Administration, Topical
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Drug Resistance, Microbial
-
Drug Therapy, Combination
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy
-
Herpes Genitalis / complications
-
Herpes Genitalis / drug therapy*
-
Herpes Genitalis / microbiology
-
Humans
-
Hydrazones / administration & dosage
-
Hydrazones / adverse effects
-
Hydrazones / therapeutic use*
-
Male
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Ribonucleotide Reductases / antagonists & inhibitors*
-
Simplexvirus / drug effects*
Substances
-
Antiviral Agents
-
Hydrazones
-
Pyridines
-
compound 348U87
-
Ribonucleotide Reductases
-
Acyclovir